"It appears that DSC127 directs MSCs to the injury site, mobilizing them to help repair wounded or burned skin, accelerate healing and reduce scar formation," said Edward J. Quilty, Chairman & CEO of Derma Sciences Inc.
이 DSC127이라는 넘을 당뇨로인해 궤양이 생긴 발에 주사를 하면, 그 쪽으로 혈관을 타고 , 혹은 주위 조직에서 ,
MSC들이 유도되어 , 궤양을 치료한다는 생각입니다.
실제로 , 동물실험에서 성공을 했다고 합니다.
지금까지는, 지방에서 MSC를 추출해서 그것을 직접 병변에 주사하는 방법이나 IV하는 방법을 써왔는데요.
그러려면, 일단 어딘가 상처를 내서 지방을 추출해야 하지요.
골수의 경우에도 마찬가지로 상처를 내야 하지요.
배아줄기세포치료는 윤리적, 안전성 문제로 조금 미뤄두고,
IPS도 아직은 실험단계라 미뤄두고,
제대혈 줄기세포는 좋은 대안이지만, 그 공여자 수가 적고, Matching되는 공여자를 만나기도 쉽지 않지요.
따라서, 이렇게 줄기세포 자체가 아닌, 줄기세포를 활성화하고 유도하는 약제들이
앞으로 실제적으로 간편하게 사용되지 않을까요?
응용범위는 낭뇨발부터, 심근경색,당뇨로 혈관이 막혀 다리궤사된 것들, 중풍등등...
혈관질환에서부터 시작하겠군요.
정말 ,MSC를 유도 활성화 한다면, MSC를 쓰는 모든 질환에 응용가능하겠네요
연골이 닳은 OA, 콧대성형, 자가면역질환등등....
알러지비염, 아토피피부염도 연고로 만들면 응용가능 하겠습니다.
DSC127 is an analog of a naturally occuring peptide, Angiotensin, and was developed at the University of Southern California. It has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization. Additionally, histological examination has shown that DSC127 accelerated collagen deposition six-fold. All these help to accelerate dermal tissue repair. The patented amino acid peptide optimizes the wound healing capabilities of Angiotensin while removing all blood pressure effects of the compound.
Extensive pre-clinical studies have demonstrated the efficacy of the compound in accelerating healing and reducing scar formation. Pre-clinical stduies thus far have shown:
Improved in-growth of host tissue into artificial skins
Accelerated healing in full thickness skin excision wounds in rats and diabetic mice
Accelerated healing in partial thickness thermal injuries in guniea pigs
Accelerated healing in a random flap skin model in rats Improved scar reduction in rats
A Phase I safety study in humans was completed in Q4 2007, and patients are currently enrolling into the Phase II efficacy study. This study of 75 patients will look at percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.
The efficacy of DSC127 and other Angiotensin analogs has been extensively studied, with numerous peer-reviewed articles published. These include:
• Rodgers KE, Roda N, Felix JC, Espinoza T, Maldonado S, diZerega G. Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice. Experimental Dermatology 2003;12(6): 784-790.
• Rodgers K, Xiong S, Felix J, Roda N, Espinoza T, Maldonado S, diZerega G. Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen 2001;9:238-250.
• Rodgers KE, Espinoza T, Felix J, Roda N, Maldonado S, diZerega acceleration of healing, Reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, norleu3-a(1-7). Plast Reconstr Surg 2003; 111:1195-1206.
• Rodgers, KE, Abiko M, Girgis W, St. Amand KM, Campeau JD, diZerega GS. Acceleration of dermal tissue repair by Angiotensin II. Wound Repair Regen 1997;5:175-183.
• Rodgers, KE, DeCherney AH, St. Amand KM, Dougherty WR, Felix JC,, Girgis W, diZerega GS. Histologic alterations in dermal repair after thermal injury: effects of topical angiotensin II. Burn Care and Rehabilitation 1997;18:381-388.
• Okuyama N, Roda N, Guerrero A, Dougherty W, Nguyen T, diZerega GS, Rodgers KE. Effect of angiotensin II on the viability, vascularity of random flaps in a rat model. Annals Plastic Surgery Res 1999;68:913-918.
• Rodgers KE, Ellefson DD, Espinoza T, Roda N, Maldonado S, diZerega GS. Effect of NorLeu3-A(1-7) on scar formation over time after full thickness incision injury in the rat. Wound Repair Regen 2005;13:309-317.
source: medicalnewtoday , http://www.dermasciences.com/subcategory.php?sid=66&id=1&show=p
댓글 없음:
댓글 쓰기